The Masonic Cancer Center University of Minnesota
Welcome,         Profile    Billing    Logout  
 4 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fujioka, Naomi
BTCRC-LUN17-127, NCT03575793: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Checkmark Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Jun 2021 - Jun 2021: Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Checkmark Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
May 2021 - May 2021: Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
Checkmark From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021
More
Completed
1/2
39
US
Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy
Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey
Lung Cancer, SCLC
09/23
07/24
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
NCT05674526: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Recruiting
1
30
US
WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion, Cetuximab - Cohort Expansion
Wugen, Inc.
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
09/25
06/26
Line, Cancer Answer
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Terminated
2
47
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
05/24
07/24
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Active, not recruiting
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
10/25
01/27
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
KYANITE-1, NCT06228326: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting
1/2
200
US
KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy
Krystal Biotech, Inc.
Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
02/28
02/28
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
10/25
11/26
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
LB-SA53-101, NCT06578624: Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Not yet recruiting
1/2
70
US
SA53-OS (phase 1), SA53-OS (phase 2)
Lamassu Bio Inc
Solid Tumor
02/26
12/28
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
1/2
178
US
TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin®
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
03/25
03/25
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
240
US
KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
Krystal Biotech, Inc.
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
07/27
07/27
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
TPST-1495-001, NCT04344795: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Active, not recruiting
1
175
US
TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab, Keytruda
Tempest Therapeutics
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
11/24
12/24
CDR404-001, NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Recruiting
1
42
Europe, US
CDR404
CDR-Life AG
Select Advanced Solid Tumors
06/26
12/27
STK-009-101, NCT05665062: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Recruiting
1
36
US
SYNCAR-001, STK-009, Cyclophosphamide, Fludarabine
Synthekine
CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
06/26
11/26
CPO-100-US-101, NCT04931823: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Active, not recruiting
1
126
US
CPO-100, DTX-HSA
Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumor
03/25
03/25
NCT05996107: Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

Suspended
1
30
US
Ribociclib, Kisqali, Postoperative Radiation Therapy
University of Michigan Rogel Cancer Center
Breast Cancer
03/26
03/30
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
100
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT04797390: A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema

Active, not recruiting
N/A
250
US
Advanced Pneumatic Compression Device (APCD), Flexitouch, Flexitouch Plus, Usual Care, Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD)
Tactile Medical, Vanderbilt University Medical Center
Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation, Lymphedema; Surgical
01/25
01/25
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33

Recruiting
N/A
36
Canada, US
VOR33
Vor Biopharma
Leukemia, Myeloid, Acute
01/40
01/40

Download Options